TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29637282

Group type: EXPERIMENTAL
Intervention: 2 g of oral TXA two hours pre-operatively (group A)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 2 g of oral TXA four hours post-operatively (group B)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 3 boluses of 2 g of oral TXA four, ten, and 16 hours post-operatively (group C)
Number of subjects: 152
Study: 29898836

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 655

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Additional antiplatelet therapy
Number of subjects: 655
Study: 27548504

Group type: EXPERIMENTAL
Intervention: Location-based exergame (Fit-Quest)
Number of subjects: 0
Study: 24490608

Group type: EXPERIMENTAL
Intervention: Nintedanib (250 mg twice daily)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Afatinib (40 mg once daily)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Combi40 (nintedanib 250 mg twice daily and afatinib 40 mg once daily)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Combi70 (nintedanib 250 mg twice daily and afatinib 70 mg once daily)
Number of subjects: 85
Study: 22933451

Group type: EXPERIMENTAL
Intervention: Self-report Beck Depression Inventory (BDI) in GENDEP
Number of subjects: 4852

Group type: COMPARATOR
Intervention: Clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS) and Hamilton Rating Scale for Depression (HRSD) in GENDEP
Number of subjects: 4852

Group type: EXPERIMENTAL
Intervention: Self-report and clinician-rated versions of Quick Inventory of Depressive Symptomatology (QIDS) in STAR*D
Number of subjects: 4852
Study: 20554869

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and Yohimbine (combined)
Number of subjects: 0
Study: 17511931

Group type: COMPARATOR
Intervention: Intervention not specified
Number of subjects: 0
Study: 16229114

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 16 mg
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg + Hydrochlorothiazide (HCT) 12.5 mg
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 16 mg + Hydrochlorothiazide (HCT) 12.5 mg
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 312
Study: 11973171

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: No insulin (Control group)
Number of subjects: 0
Study: 10470991

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg 3x daily for 1 day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7890074

Group type: EXPERIMENTAL
Intervention: Captopril, 6.25 mg orally twice daily for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no ACE inhibitor)
Number of subjects: 12
Study: 2095164

Group type: EXPERIMENTAL
Intervention: Infusion of 81 mval/day MgSO4 for 3 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: No infusion (Control group)
Number of subjects: 42
Study: 90601

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31678968

Group type: COMPARATOR
Intervention: Placebo surgery (sham surgeries)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial menisectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression
Number of subjects: 0
Study: 27932278

Group type: EXPERIMENTAL
Intervention: Spacing anti-TNF
Number of subjects: 137

Group type: COMPARATOR
Intervention: Maintaining anti-TNF
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 137
Study: 23860293

Group type: EXPERIMENTAL
Intervention: Corrective exercise program 4 times per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23431210

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (pelvic-floor muscle exercises and bladder control strategies)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (bladder control strategies)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (pelvic-floor muscle exercises)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (exercise adherence predictors)
Number of subjects: 296
Study: 21110732

Group type: EXPERIMENTAL
Intervention: Bilateral tDCS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Extra-cephalic tDCS
Number of subjects: 10
Study: 20027344

Group type: EXPERIMENTAL
Intervention: Anaferon (pediatric formulation)
Number of subjects: 0
Study: 17346383

Group type: EXPERIMENTAL
Intervention: Befriending intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 44
Study: 15994143

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control (standard medical care)
Number of subjects: 252
Study: 12140794

Group type: EXPERIMENTAL
Intervention: Resistance training (hypertrophic maximal strength training) for 12 weeks, initially two times, then three times a week
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Resistance training (hypertrophic maximal strength training)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study: 9537454

Group type: EXPERIMENTAL
Intervention: Combination therapy with thymosin alpha1 (TA1) and interferon (IFN)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Interferon (IFN) alone
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (untreated controls)
Number of subjects: 109
Study: 7852226

Group type: EXPERIMENTAL
Intervention: Gugulipid (1 gm)
Number of subjects: 17
Study: 2531052

Group type: EXPERIMENTAL
Intervention: Dopaminergic blockade with metoclopramide (n = 5) during water immersion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dopaminergic blockade with domperidone (n = 5) during water immersion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water immersion alone (control for both groups)
Number of subjects: 10
Study: 1053432

Group type: EXPERIMENTAL
Intervention: Nasal spray containing purified IgG from a subject with a high titre of IgG antibody to ragweed antigen E
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nasal spray containing phosphate-buffered saline (PBS) with human serum albumin
Number of subjects: 14
Study: 31177131

Group type: EXPERIMENTAL
Intervention: Minicholecystectomy (MC), n=58
Number of subjects: 110

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC), n=52
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both MC and LC groups
Number of subjects: 110
Study: 26423058

Group type: EXPERIMENTAL
Intervention: Web-based culture-specific intervention for improving mammography utilization
Number of subjects: 136
Study: 26051498

Group type: EXPERIMENTAL
Intervention: iLTS-D
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fastrach
Number of subjects: 64
Study: 23985254

Group type: EXPERIMENTAL
Intervention: Capecitabine and radiotherapy (Cap-CRT)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Capecitabine and oxaliplatin plus radiotherapy (Cap-Oxa-CRT)
Number of subjects: 400
Study: 21751889

Group type: EXPERIMENTAL
Intervention: Constant CGM group (12 patients on insulin pump with glucose sensor, 24 h/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intermittent CGM group (13 patients on insulin pump with intermittent glucose sensor, 14 days/month)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Constant CGM group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intermittent CGM group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 18214709

Group type: EXPERIMENTAL
Intervention: Low-dose IV cyclophosphamide (LD-CYC) 500 mg/dose for six fortnightly pulses (cumulative dose 3 g) followed by azathioprine (AZA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: High-dose IV cyclophosphamide (HD-CYC) maximum of 1 g/dose for six monthly pulses followed by two quarterly pulses, followed by azathioprine (AZA)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-dose IV cyclophosphamide (LD-CYC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: High-dose IV cyclophosphamide (HD-CYC)
Number of subjects: 46
Study: 16769598

Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prasugrel 75 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prasugrel 2.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15446552

Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide and etoposide combination or carboplatin combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide and doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total surgical excision of residual lung metastases
Number of subjects: 0
Study: 11376923

Group type: EXPERIMENTAL
Intervention: Methadone tapering plus amantadine (200-300 mg per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9422413

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 303
Study: 8357779

Group type: EXPERIMENTAL
Intervention: Cicletanine (200 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2892499

Group type: EXPERIMENTAL
Intervention: Diphenhydramine, 50 mg (H1 receptor antagonist) and Cimetidine, 300 mg (H2 receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study: 29332237

Group type: EXPERIMENTAL
Intervention: 1 g of acetaminophen
Number of subjects: 13

Group type: COMPARATOR
Intervention: 1 g of maltodextrin (placebo)
Number of subjects: 13
Study: 27567966

Group type: EXPERIMENTAL
Intervention: Combined nicotine replacement therapy/placebo and contingency management for attendance/abstinence
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 26653027

Group type: EXPERIMENTAL
Intervention: Extraction string group
Number of subjects: 114

Group type: COMPARATOR
Intervention: No string group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114
Study: 24348909

Group type: EXPERIMENTAL
Intervention: Isometric contraction of the right arm (10‐20% of maximal voluntary force) with left arm passively moved by a motorized manipulandum.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isometric contraction of the right arm (10‐20% of maximal voluntary force) with left arm remaining static.
Number of subjects: 20
Study: 20876621

Group type: EXPERIMENTAL
Intervention: Nebulized colistimethate sodium (CMS) equivalent to 75 mg of colistin base in 4 mL of NSS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nebulized sterile normal saline (NSS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nebulized colistimethate sodium (CMS)
Number of subjects: 100
Study: 18096125

Group type: EXPERIMENTAL
Intervention: Group A (practiced the task)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (viewed an error‐instruction video, practiced, followed by re‐assessment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 16874157

Group type: EXPERIMENTAL
Intervention: Home-based cardiac exercise program (HBCEP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study: 12811255

Group type: EXPERIMENTAL
Intervention: Kidney transplantation (Tx)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Norepinephrine and N‐monomethyl‐L‐arginine
Number of subjects: 8
Study: 11015164

Group type: EXPERIMENTAL
Intervention: 12.5 mg hydrochlorothiazide per day
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide per day
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 8969393

Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl-midazolam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 1459387

Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment of hypertension (NPTH)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Traditional pharmacological treatments of hypertension (Control)
Number of subjects: 250
Study: 4085523

Group type: EXPERIMENTAL
Intervention: Cadralazine 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cadralazine 10 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cadralazine 20 mg
Number of subjects: 6
Study: 30109735

Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme based on healthy eating, physical exercise, and cognitive behavioural therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme
Number of subjects: 74
Study: 27504006

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure target (<120 mm Hg)
Number of subjects: 4266

Group type: COMPARATOR
Intervention: Standard systolic blood pressure target (<140 mm Hg)
Number of subjects: 4266

Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension (OH)
Number of subjects: 4266

Group type: EXPERIMENTAL
Intervention: Primary composite outcome (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death)
Number of subjects: 4266
Study: 24323034

Group type: EXPERIMENTAL
Intervention: goserelin combined with dutasteride (ZD)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: bicalutamide and dutasteride (ZBD)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: bicalutamide, dutasteride, and ketoconazole (ZBDK)
Number of subjects: 35

Group type: COMPARATOR
Intervention: combined androgen blockade with luteinizing hormone‐releasing hormone agonist and bicalutamide (Control)
Number of subjects: 35
Study: 22360332

Group type: EXPERIMENTAL
Intervention: 2% L-carnitine applied topically for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% or 1% L-carnitine in vitro
Number of subjects: 0
Study: 20482535

Group type: EXPERIMENTAL
Intervention: Carbetocin 100 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxytocin 5 IU intravenously
Number of subjects: 0
Study: 18382819

Group type: EXPERIMENTAL
Intervention: Exercise therapy group (n = 15)
Number of subjects: 30
Study: 16006908

Group type: EXPERIMENTAL
Intervention: 60 shocks per minute
Number of subjects: 220

Group type: COMPARATOR
Intervention: 120 shocks per minute
Number of subjects: 220
Study: 12548201

Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate/5 microg ethinyl estradiol
Number of subjects: 357

Group type: COMPARATOR
Intervention: Conjugated equine estrogens/medroxyprogesterone acetate
Number of subjects: 357
Study: 10611554

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 microg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg/day
Number of subjects: 30
Study: 9050657

Group type: EXPERIMENTAL
Intervention: Prophylactic mesosalpingeal dilute vasopressin injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: No vasopressin (control group)
Number of subjects: 40
Study: 1815973

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 5 mg orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 10 mg orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 20 mg orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 0.1 mg intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 0.5 mg intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (all doses)
Number of subjects: 8
Study: 6292803

Group type: EXPERIMENTAL
Intervention: Doxycycline 300 mg orally
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g intramuscularly
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 600 mg orally
Number of subjects: 135

Group type: COMPARATOR
Intervention: Co-trimoxazole (CTM)
Number of subjects: 135
Study: 31849138

Group type: EXPERIMENTAL
Intervention: 7-week work-place smoking cessation group training programme with financial incentives (gift vouchers of €350 for 12 months' continuous abstinence)
Number of subjects: 604

Group type: COMPARATOR
Intervention: 7-week work-place smoking cessation group training programme without financial incentives
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: 7-week work-place smoking cessation group training programme with financial incentives
Number of subjects: 604
Study: 31567943

Group type: EXPERIMENTAL
Intervention: High VO2max group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Low VO2max group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: VO2max
Number of subjects: 119
Study: 28940320

Group type: EXPERIMENTAL
Intervention: Prevention of Post‐Rape Stress (PPRS) video intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Pleasant Imagery and Relaxation Instruction (PIRI)
Number of subjects: 154
Study: 25785452

Group type: EXPERIMENTAL
Intervention: Group peer support
Number of subjects: 1299

Group type: EXPERIMENTAL
Intervention: Group peer support (attended at least once)
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1299
Study: 23455861

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chest physiotherapy
Number of subjects: 45
Study: 21868709

Group type: EXPERIMENTAL
Intervention: Directly supervised exercise training for 12 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Home-based exercise training for 12 weeks
Number of subjects: 35
Study: 19106795

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate for lowering blood pressure
Number of subjects: 565
Study: 17003953

Group type: EXPERIMENTAL
Intervention: Foot reflexology treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Nonspecific foot massage control
Number of subjects: 109
Study: 15470966

Group type: EXPERIMENTAL
Intervention: Morning light (6000 lux) for 1.5 hours daily for 4 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Evening light (6000 lux) for 1.5 hours daily for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment (sham negative ion generators) for 1.5 hours daily for 4 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All treatments (morning light, evening light, placebo)
Number of subjects: 26
Study: 15259283

Group type: EXPERIMENTAL
Intervention: E2/NETA (estradiol 2 mg plus norethisterone acetate 1 mg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 9987624

Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 64

Group type: COMPARATOR
Intervention: 0.25% timolol
Number of subjects: 64
Study: 7487618

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate (0.2%) given topically twice daily for 1 week
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vehicle-treated contralateral control eyes
Number of subjects: 21
Study: 2248390

Group type: COMPARATOR
Intervention: Bupivacaine epidural anesthesia without fentanyl (group 1)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bupivacaine epidural anesthesia with 100 micrograms of fentanyl (group 2)
Number of subjects: 2
Study: 6990669

Group type: EXPERIMENTAL
Intervention: Plastic wound drape (Vi-drape)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group (no drape)
Number of subjects: 289
Study: 30665882

Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) including decision aids
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (consultation with the hospital social service)
Number of subjects: 115
Study: 28422874

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine at 0.2 μg/kg/h
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine at 0.4 μg/kg/h
Number of subjects: 93

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 93
Study: 26074397

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 2887

Group type: COMPARATOR
Intervention: Sequential docetaxel
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Docetaxel in ER-positive tumours with Ki67≥14%
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Docetaxel in ER-positive patients with high Ki67
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Taxanes in highly proliferative ER-positive disease
Number of subjects: 2887
Study: 25039244

Group type: EXPERIMENTAL
Intervention: Topical 5% potassium hydroxide (KOH) solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical 0.5% 5‐fluorouracil (5‐FU) and 10% salicylic acid (SA) combination
Number of subjects: 60
Study: 22647439

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl 1.5 mcg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous morphine 0.1 mg/kg
Number of subjects: 30
Study: 19605829

Group type: EXPERIMENTAL
Intervention: Disclosure of APOE genotyping results
Number of subjects: 162

Group type: COMPARATOR
Intervention: Nondisclosure of APOE genotyping results
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Disclosure subgroup carrying the APOE epsilon4 allele
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Epsilon4-negative subgroup
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Baseline scores for anxiety and depression
Number of subjects: 162
Study: 17445898

Group type: EXPERIMENTAL
Intervention: Preoperative sub‐Tenon's capsule injection of 3 ml of 0.75% ropivacaine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (sub‐Tenon's capsule injection of 3 ml of saline)
Number of subjects: 98
Study: 16113430

Group type: EXPERIMENTAL
Intervention: Fluticasone (inhaled corticosteroid)
Number of subjects: 0